Advisor Group Holdings Inc. Purchases 578 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Advisor Group Holdings Inc. lifted its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 8.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,287 shares of the biotechnology company’s stock after purchasing an additional 578 shares during the quarter. Advisor Group Holdings Inc.’s holdings in Sarepta Therapeutics were worth $566,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Pinnacle Associates Ltd. grew its stake in Sarepta Therapeutics by 3.2% in the second quarter. Pinnacle Associates Ltd. now owns 113,986 shares of the biotechnology company’s stock valued at $8,861,000 after purchasing an additional 3,490 shares in the last quarter. Advisors Asset Management Inc. raised its holdings in Sarepta Therapeutics by 16.1% in the 2nd quarter. Advisors Asset Management Inc. now owns 23,742 shares of the biotechnology company’s stock valued at $1,846,000 after acquiring an additional 3,296 shares in the last quarter. GPS Wealth Strategies Group LLC acquired a new position in Sarepta Therapeutics in the 2nd quarter valued at $35,000. Lehman & Derafelo Financial Resources LLC raised its holdings in shares of Sarepta Therapeutics by 8.7% during the 2nd quarter. Lehman & Derafelo Financial Resources LLC now owns 12,517 shares of the biotechnology company’s stock worth $973,000 after buying an additional 1,000 shares in the last quarter. Finally, NEXT Financial Group Inc raised its holdings in shares of Sarepta Therapeutics by 10.4% during the 2nd quarter. NEXT Financial Group Inc now owns 1,896 shares of the biotechnology company’s stock worth $147,000 after buying an additional 179 shares in the last quarter. 79.33% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms have commented on SRPT. Credit Suisse Group upped their price target on Sarepta Therapeutics from $72.00 to $75.00 and gave the company a “neutral” rating in a research report on Thursday, August 5th. Guggenheim raised Sarepta Therapeutics from a “neutral” rating to a “buy” rating in a research note on Wednesday, September 15th. JPMorgan Chase & Co. raised Sarepta Therapeutics from an “underweight” rating to a “neutral” rating and dropped their price target for the stock from $92.00 to $87.00 in a research note on Thursday, August 5th. Morgan Stanley lowered their price objective on Sarepta Therapeutics from $93.00 to $90.00 and set an “equal weight” rating for the company in a research note on Monday, August 16th. Finally, Zacks Investment Research raised Sarepta Therapeutics from a “sell” rating to a “hold” rating and set a $84.00 target price for the company in a report on Wednesday, August 11th. Eleven research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $125.39.

Shares of SRPT stock opened at $85.67 on Tuesday. Sarepta Therapeutics, Inc. has a 1 year low of $65.30 and a 1 year high of $181.83. The firm has a fifty day moving average price of $75.48 and a 200-day moving average price of $76.28. The company has a debt-to-equity ratio of 2.25, a current ratio of 5.33 and a quick ratio of 4.70. The company has a market cap of $6.84 billion, a price-to-earnings ratio of -10.68 and a beta of 1.38.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, August 4th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.27. Sarepta Therapeutics had a negative net margin of 105.73% and a negative return on equity of 94.90%. The firm had revenue of $164.09 million during the quarter, compared to the consensus estimate of $161.95 million. During the same quarter in the previous year, the firm posted ($1.93) EPS. The company’s revenue for the quarter was up 19.5% compared to the same quarter last year. Equities research analysts expect that Sarepta Therapeutics, Inc. will post -7.46 EPS for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Recommended Story: Do You Need a Fiduciary?

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.